Alveolitis and delayed healing: the challenge of photonic therapies

Dry socket remains a major post-extraction complication whose clinical management, particularly in infected environments, requires effective adjuvant protocols to limit healing delays. This experimental study specifically addresses this challenge by evaluating the impact of antimicrobial photodynamic therapy (aPDT) and photobiomodulation (PBM) on the alveolar repair process.

The main objective of the authors was to histologically analyze the kinetics of bone regeneration within infected wounds in 48 rats following the extraction of the upper incisor and the induction of experimental alveolar osteitis. The study aimed to compare the effectiveness of four distinct protocols: a control group without treatment, irrigation with methylene blue alone (100 µg/mL), low-level laser irradiation alone (PBM: 685nm, 12J), and the combination of both (aPDT).

The hypothesis tested is based on the ability of photonic therapies to minimize the deleterious effects of alveolar infection and to accelerate the timeline of bone repair. The researchers thus sought to determine whether aPDT, through its dual antimicrobial and biostimulating effect, outperforms conventional approaches or the isolated use of light in restoring the architectural integrity of the socket.

Methodology: Experimental protocol and photonic parameters

This in vivo study was conducted on a sample of 48 rats. Following the extraction of the upper right incisor, experimental alveolar osteitis was induced in all subjects before their random distribution into four distinct groups (n=12 per group):

• Group C (Control): No therapeutic intervention, intra- or extra-alveolar.
• FS Group (Photosensitizer): Single alveolar irrigation with methylene blue at a concentration of 100 µg/mL.
• PBM Group (Photobiomodulation): Low-power laser irradiation (685 nm, 0.05 W) for 240 seconds, delivering a total energy of 12 J.
• aPDT Group (Photodynamic Therapy): Application of methylene blue (100 µg/mL) with a pre-irradiation time of 60 seconds, followed immediately by laser irradiation according to the same parameters as the FBM group (685 nm, 0.05 W, 240 s, 12 J).

The evaluation of the bone repair process was based on a descriptive histological analysis performed on three specific alveolar sites. The animals were euthanized at four post-operative intervals: 7, 15, 21, and 28 days, allowing for precise chronological monitoring of healing kinetics under the influence of the different protocols.

Results: A marked acceleration of healing under aPDT

Histological analysis of the alveolar repair process, conducted on 48 rats divided into four groups (n=12), reveals significant disparities in the chronology of bone regeneration between photonic protocols and control groups.

Comparison of repair kinetics by group

Histological observations carried out on post-operative days 7, 15, 21, and 28 allow for the following comparative table to be drawn up:

Qualitative analysis and tissue dynamics

The study highlights major structural differences according to the treatment modalities:

• Inhibition of delayed healing: While induced alveolitis caused systematic delayed healing in the control group (C), the isolated use of the photosensitizer (FS) was sufficient to minimize the deleterious effects of infection on bone remodeling.
• Effectiveness of photonic therapies: The groups that benefited from laser irradiation (PBM and aPDT) showed superior bone filling dynamics. The laser parameters used (685nm, 240 seconds of exposure for a total energy of 12J) promoted earlier tissue maturation.
• Superiority of aPDT: The combination of methylene blue with a 60-second pre-irradiation time followed by laser therapy produced the best histological results, suggesting a synergy between the antimicrobial effect of the photosensitizer and the biostimulating effect of light.

In conclusion, the data show that while FS alone improves the inflammatory response, it is the laser-photosensitizer combination (aPDT) that truly optimizes the repair kinetics of the infected socket.

Analysis of results and clinical perspectives

The data from this experimental study conducted on 48 rats clearly demonstrate that induced alveolar infection disrupts healing homeostasis, leading to a significant delay in bone repair in the control group. The major interest of this work lies in the comparison of healing kinetics between photonic therapies and simple irrigation with a photosensitizer.

The use of aPDT (combining methylene blue at 100 µg/mL and a 685 nm laser delivering 12J) proved to be the most effective approach for restoring a physiological repair timeline, surpassing photobiomodulation (PBM) alone. A notable point for the practitioner is the intrinsic effect of methylene blue (FS group): even without laser activation, its use minimized the deleterious impact of alveolar osteitis on the bone tissue compared to the control group, suggesting a beneficial antiseptic action from the initial phases.

However, the study has inherent limitations due to its animal model and the restricted size of the groups per euthanasia period (7, 15, 21, and 28 days). Although the results are statistically favorable to aPDT for accelerating alveolar socket healing, direct extrapolation to human clinical practice requires careful consideration, particularly regarding energy density parameters and pre-irradiation protocols (fixed at 60 seconds in this study).

Summary of results

This experimental study on 48 rats demonstrates that antimicrobial photodynamic therapy (aPDT), combining methylene blue (100 µg/mL) and laser irradiation (685 nm, 12 J), significantly accelerates alveolar bone repair in cases of alveolar osteitis. Compared to the control group (C) which shows delayed healing, aPDT and photobiomodulation (PBM) alone reduced repair times, with aPDT providing the most effective histological response over a 28-day period.

In concrete terms, for the practitioner:

• Optimization of dry socket treatment: In the event of an infected site or delayed healing, the integration of aPDT (photosensitizer + red laser) allows for a shift from simple disinfection to a genuine acceleration of clinical osteogenesis.
• Target parameters: Data suggest the efficacy of a 685 nm laser protocol (0.05 W, 240 s) coupled with a 60-second pre-irradiation time for methylene blue to maximize antimicrobial and regenerative synergy.
• Alternative to conventional antiseptics: While methylene blue alone already minimizes the deleterious effects of alveolar osteitis, its combination with laser (aPDT) is essential to achieve qualitatively superior and faster bone repair.

Technical lexicon of the study on experimental alveolar osteitis

Experimental alveolitis: Pathological state induced in this study in 48 rats following extraction of the upper right incisor, characterized by infection and delayed bone healing, simulating dry socket encountered in human clinical practice.

aPDT (Antimicrobial Photodynamic Therapy): Therapeutic procedure combining the application of a photosensitizer (methylene blue) and irradiation by a low-power laser to generate an antimicrobial effect and stimulate tissue repair.

PBM (Photobiomodulation Therapy): Use of low-intensity laser radiation (here 685 nm, 0.05W) without the addition of a photosensitizing agent, aiming to modulate cellular functions to accelerate alveolar bone regeneration.

Photosensitizer (PS): Exogenous chemical agent, represented here by methylene blue at a concentration of 100 µg/mL, capable of capturing laser light energy to induce a therapeutic photochemical reaction.

Pre-irradiation time: 60-second interval respected in the study's aPDT protocol between the irrigation of the socket with methylene blue and laser activation, allowing for optimal diffusion of the product.

Low-level laser : Phototherapy device set for the study at a wavelength of 685 nm, delivering a dose of 12 Joules over a duration of 240 seconds per alveolar site.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all responsibility regarding the use of this information. This document is not intended for patients or the general public.